Observation of the impact of PAD and BP screening on CV risk uptake in men and women being screened Circulatory System
Conditions
Interventions
Observation of a pilot PAD and BP screening programme vs AAA screening in men regarding the impact on attendance. Post-screening (i.e. a non-research activity), men and women in follow up (research ac
Sponsors
University of Leicester
Eligibility
Sex/Gender
All
Age
60 Years to 69 Years
Inclusion criteria
Inclusion criteria: Men's study: 1. Willing and able to give informed consent 2. Male 3. Aged 65 years or in the year of their 65th birthday 4. In receipt of an invitation to primary routine AAA screening and have attended for screening 5. An ability to understand verbal and written English Women's study: 1. Willing and able to give informed consent 2. Female 3. Aged 60 to 69 years 4. Registered at the Willows Health group of GP practices under University Hospitals of Leicester (UHL) 5. An ability to understand verbal and written English
Exclusion criteria
Exclusion criteria: Men's study: 1. Men being re-invited for a second appointment having not attended for their primary screening appointment (unless involvement with the study specifically requested upon re-invitation)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Attendance measured as part of the Pilot Screening Programme using the UK AAA Screening Programme methods at baseline for all individuals invited, not just participants in the follow-up, interview, and GENEActiv studies 2. Quality of life measured using EQ-5D-5L at baseline, 3 months, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years as part of the follow-up study | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Prevalence of PAD and high BP measured using a questionnaire at baseline as part of the Pilot Screening Programme and baseline, 3 months, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years as part of the follow-up study 2. Prevalence of undiagnosed PAD and high BP measured using a questionnaire at baseline, 3 months, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years as part of the follow-up study 3. Prevalence of untreated PAD and high BP measured using a questionnaire at baseline, 3 months, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years as part of the follow-up study. 4. Acceptability of screening test measured by a question on a scale of 1 to 10 after screening as part of follow-up study. Acceptability of the screening is also assessed by interview immediately after screening for those that screen positive for PAD and/or high BP. Acceptability is also assessed by interview after 3 months for the managers and again for those that screen positive for PAD and/or high BP at 6 months. 5. Training requirements for AAA+PAD+BP screening determined from the qualitative interviews with screening staff and managers after screening, 3 months, and throughout screening activities and following clinical training under the pilot screening programme 6. Additional time required for PAD+BP screening vs AAA screening in men measured by collecting the start and end times of appointments at the screening appointment as part of the service evaluation of the clinical pilot screening programme 7. Uptake of CV risk management in men and women that screen positive for PAD and/or high BP, measured by questionnaire (including IPAQ) at 3 months, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years as part of the follow-up study and from activity data collected by wearing the GENEActiv activity device monitor at baseline and 6 months. Uptake of CV risk management will also be assessed by interviews with those that screen positive for PAD and/or high BP | — |
Countries
England, Scotland, United Kingdom
Contacts
Public ContactSian Baldock
Outcome results
None listed